Fibrosis is a wound-healing process that results in tissue scarring and organ dysfunction. Several novel mechanisms of fibrogenesis have been discovered recently. In this review, we focus on the role of poly-ADP ribose polymerase (PARP) in major organ fibrosis, such as lungs, heart, liver, and kidneys. PARP is a dynamic enzyme that modulates different cellular proteins by the addition of PAR groups and mediates an array of cellular events in both normal physiological and pathophysiological states. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently approved several PARP inhibitors, such as olaparib, niraparib, talazoparib, and rucaparib, for the treatment of ovarian and germline BRCA-mutant breast cancers. Consequently, repurposing these drugs could provide an opportunity to counter organ fibrosis.

纤维化是一种伤口愈合过程，会导致组织瘢痕形成和器官功能障碍。最近发现了几种新的纤维发生机制。在这篇综述中，我们关注聚 ADP 核糖聚合酶 (PARP) 在肺、心脏、肝脏和肾脏等主要器官纤维化中的作用。PARP 是一种动态酶，它通过添加 PAR 基团来调节不同的细胞蛋白质，并在正常生理和病理生理状态下介导一系列细胞事件。美国食品和药物管理局 (FDA) 和欧洲药品管理局 (EMA) 最近批准了几种 PARP 抑制剂，如奥拉帕利、尼拉帕利、他拉唑帕利和鲁卡帕利，用于治疗卵巢癌和生殖系 BRCA 突变型乳腺癌。因此，重新利用这些药物可以提供对抗器官纤维化的机会。